Breast cancer progression to other organs
Keywords:
metastasis, estrogen receptor (ER), progesterone receptor (PR), HER2, breast cellAbstract
Breast cancer has become very common among women and is the major cause of morbidity. The progression of breast cancer and the formation of secondary tumors in other organs is of major concern. Relapse and recurrence of breast cancer worsen the situation. Multiple genes get altered facilitating metastasis of cancer and downregulation/upregulation of many genes causes variations in molecular expression leading to progression in breast cancer cells. Mainly subtypes of breast cancer are distinct in the expression of hormone receptors (HR) and other proteins like ER, PR, HER2. Breast cancer can invade distant organs commonly in the bone, brain, lung, liver, and also the local region like the chest wall, and lymph nodes. Understanding the mechanism of cancer progression and molecules involved in breast cancer will help in developing therapies to prevent metastasis and find cures for breast cancer. In this review, the biomolecules such as ER, PR, HER2, etc. and the genes involved in breast cancer during its progression, and the mechanisms involved in metastasis have been discussed.
Downloads
References
Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The American Journal of Human Genetics. 1998 Mar 1;62(3):676-89.
Yates LR, Knappskog S, Wedge D, Farmery JH, Gonzalez S, Martincorena I, Alexandrov LB, Van Loo P, Haugland HK, Lilleng PK, Gundem G. Genomic evolution of breast cancer metastasis and relapse. Cancer cell. 2017 Aug 14;32(2):169-84.
Bell JC, Ilkow CS. A viro-immunotherapy triple play for the treatment of glioblastoma. Cancer Cell. 2017 Aug 14;32(2):133-4.
Guan X. Cancer metastases: challenges and opportunities. Acta pharmaceutica sinica B. 2015 Sep 1;5(5):402-18.
Krøigård AB, Larsen MJ, Lænkholm AV, Knoop AS, Jensen JD, Bak M, Mollenhauer J, Thomassen M, Kruse TA. Identification of metastasis driver genes by massive parallel sequencing of successive steps of breast cancer progression. PLoS One. 2018 Jan 2;13(1):e0189887.
Kimbung S, Johansson I, Danielsson A, Veerla S, Brage SE, Stolt MF, Skoog L, Carlsson L, Einbeigi Z, Lidbrink E, Linderholm B. Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis–Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer. Clinical cancer research. 2016 Jan 1;22(1):146-57.
Kimbung S, Johansson I, Danielsson A, Veerla S, Brage SE, Stolt MF, Skoog L, Carlsson L, Einbeigi Z, Lidbrink E, Linderholm B. Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis–Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer. Clinical cancer research. 2016 Jan 1;22(1):146-57.
Scully OJ, Bay BH, Yip G, Yu Y. Breast cancer metastasis. Cancer genomics & proteomics. 2012 Sep 1;9(5):311-20.
Welch DR, Wei LL. Genetic and epigenetic regulation of human breast cancer progression and metastasis. Endocrine-Related Cancer. 1998 Sep 1;5(3):155-97.
Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell. 2006 Nov 17;127(4):679-95.
O'Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, André F, Loibl S, Loi S, Garcia-Murillas I, Cristofanilli M. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer discovery. 2018 Nov 1;8(11):1390-403.
Tsai YP, Wu KJ. Hypoxia-regulated target genes implicated in tumor metastasis. Journal of biomedical science. 2012 Dec;19(1):1-7.
Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, Reuben J, Cristofanilli M, Dontu G, Bidaut L, Valero V, Hortobagyi GN. Breast cancer metastasis: challenges and opportunities.
Ozoran E, Trabulus FD, Erhan D, Batar B, Guven M. Association of XRCC3, XRCC4, BAX and BCL-2 Polymorphisms with the Risk of Breast Cancer.
Weigelt B, Peterse JL, Van't Veer LJ. Breast cancer metastasis: markers and models. Nature reviews cancer. 2005 Aug;5(8):591-602.
Guo L, Chen Y, Luo J, Zheng J, Shao G. YAP 1 overexpression is associated with poor prognosis of breast cancer patients and induces breast cancer cell growth by inhibiting PTEN. FEBS Open Bio. 2019 Mar;9(3):437-45.
Krøigård AB, Larsen MJ, Lænkholm AV, Knoop AS, Jensen JD, Bak M, Mollenhauer J, Thomassen M, Kruse TA. Identification of metastasis driver genes by massive parallel sequencing of successive steps of breast cancer progression. PLoS One. 2018 Jan 2;13(1):e0189887.
Bell R, Barraclough R, Vasieva O. Gene expression meta-analysis of potential metastatic breast cancer markers. Current molecular medicine. 2017 Mar 1;17(3):200-10.
Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J, Hallberg E, Moore R, Thomas A, Lilyquist J, Feng B. Associations between cancer predisposition testing panel genes and breast cancer. JAMA oncology. 2017 Sep 1;3(9):1190-6.
Donepudi MS, Kondapalli K, Amos SJ, Venkanteshan P. Breast cancer statistics and markers. Journal of cancer research and therapeutics. 2014 Jul 1;10(3):506.
Rosen EM, Fan S, Pestell RG, Goldberg ID. BRCA1 gene in breast cancer. Journal of cellular physiology. 2003 Jul;196(1):19-41.
Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. Critical Reviews™ in Oncogenesis. 2013;18(1-2).
Thomassen M, Tan Q, Kruse TA. Gene expression meta-analysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis. Breast cancer research and treatment. 2009 Jan;113(2):239-49.
Broustas CG, Lieberman HB. DNA damage response genes and the development of cancer metastasis. Radiation research. 2014 Feb;181(2):111-30.
Cha S, Lee E, Won HH. Comprehensive characterization of distinct genetic alterations in metastatic breast cancer across various metastatic sites. NPJ breast cancer. 2021 Jul 16;7(1):1-1.
Xu K, Wang R, Li X, Chen Q, Gao F, Liu Y, Zhu C, Li X, Tian W, Zhou G, Guan X. ERβ Suppresses the AR Oncogenic Effects in Triple-Negative Breast Cancer. Available at SSRN 4068265.
Yang F, Zhou X, Miao X, Zhang T, Hang X, Tie R, Liu N, Tian F, Wang F, Yuan J. MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis. Breast cancer research and treatment. 2014 May;145(1):23-32.
Li K, Li GD, Sun LY, Li XQ. PTEN and SHIP: Impact on lymphatic metastasis in breast cancer. Journal of cancer research and therapeutics. 2018 Dec 1;14(12):937.
Yuan M, Tomlinson V, Lara R, Holliday D, Chelala C, Harada T, Gangeswaran R, Manson-Bishop C, Smith P, Danovi SA, Pardo O. Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death & Differentiation. 2008 Nov;15(11):1752-9.
Fang W, Ma Y, Yin JC, Hong S, Zhou H, Wang A, Wang F, Bao H, Wu X, Yang Y, Huang Y. Comprehensive genomic profiling identifies novel genetic predictors of response to anti–PD-(L) 1 therapies in non–small cell lung cancer. Clinical Cancer Research. 2019 Aug 15;25(16):5015-26.
Yang R, Xing L, Zheng X, Sun Y, Wang X, Chen J. The circRNA circAGFG1 acts as a sponge of miR-195-5p to promote triple-negative breast cancer progression through regulating CCNE1 expression. Molecular cancer. 2019 Dec;18(1):1-9.
Rashid NS, Grible JM, Clevenger CV, Harrell JC. Breast cancer liver metastasis: current and future treatment approaches. Clinical & experimental metastasis. 2021 Jun;38(3):263-77.
Ma R, Feng Y, Lin S, Chen J, Lin H, Liang X, Zheng H, Cai X. Mechanisms involved in breast cancer liver metastasis. Journal of translational medicine. 2015 Dec;13(1):1-0.
Ji L, Cheng L, Zhu X, Gao Y, Fan L, Wang Z. Risk and prognostic factors of breast cancer with liver metastases. BMC cancer. 2021 Dec;21(1):1-5.
Stessels F, Van den Eynden G, Van der Auwera I, Salgado R, Van den Heuvel E, Harris AL, Jackson DG, Colpaert CG, Van Marck EA, Dirix LY, Vermeulen PB. Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. British journal of cancer. 2004 Apr;90(7):1429-36.
Ji L, Fan L, Zhu X, Gao Y, Wang Z. A Prognostic Model for Breast Cancer With Liver Metastasis. Frontiers in oncology. 2020:1342.
Munir N, Rasool NG, Batool Y, Yousaf R, Basharat T, Irfan S, Sharif H, Zaka F. A Review on Identification of Novel Biomarkers to Identify Genes in Breast Cancer.
Thalor A, Joon HK, Singh G, Roy S, Gupta D. Machine learning assisted analysis of breast cancer gene expression profiles reveals novel potential prognostic biomarkers for triple-negative breast cancer. Computational and structural biotechnology journal. 2022 Jan 1;20:1618-31.
Biermann J. Tumour evolution and novel biomarkers in breast cancer.
Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World journal of clinical oncology. 2014 Aug 10;5(3):412.
Erin N, Wang N, Xin P, Bui V, Weisz J, Barkan GA, Zhao W, Shearer D, Clawson GA. Altered gene expression in breast cancer liver metastases. International journal of cancer. 2009 Apr 1;124(7):1503-16.
Chen W, Hoffmann AD, Liu H, Liu X. Organotropism: new insights into molecular mechanisms of breast cancer metastasis. NPJ precision oncology. 2018 Feb 16;2(1):1-2.
Chen X, Zheng Z, Chen L, Zheng H. MAPK, NFκB, and VEGF signaling pathways regulate breast cancer liver metastasis. Oncotarget. 2017 Nov 24;8(60):101452.
Ouhtit A, Abd Elmageed ZY, Abdraboh ME, Lioe TF, Raj MH. In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver. The American journal of pathology. 2007 Dec 1;171(6):2033-9.
Tabariès S, Ouellet V, Hsu BE, Annis MG, Rose AA, Meunier L, Carmona E, Tam CE, Mes-Masson AM, Siegel PM. Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases. Breast cancer research. 2015 Dec;17(1):1-8.
Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006 Mar 1;107(5):1761-7.
Liu H, Li X, Li H, Feng L, Sun G, Sun G, Wu L, Hu Y, Liu L, Wang H. Potential molecular mechanisms and clinical progress in liver metastasis of breast cancer. Biomedicine & Pharmacotherapy. 2022 May 1;149:112824.
Senbanjo LT, Chellaiah MA. CD44: a multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells. Frontiers in cell and developmental biology. 2017 Mar 7;5:18.
Jin L, Han B, Siegel E, Cui Y, Giuliano A, Cui X. Breast cancer lung metastasis: Molecular biology and therapeutic implications. Cancer biology & therapy. 2018 Oct 3;19(10):858-68.
Xiao W, Zheng S, Liu P, Zou Y, Xie X, Yu P, Tang H, Xie X. Risk factors and survival outcomes in patients with breast cancer and lung metastasis: a population‐based study. Cancer medicine. 2018 Mar;7(3):922-30.
Jin X, Mu P. Targeting breast cancer metastasis. Breast cancer: basic and clinical research. 2015 Jan;9:BCBCR-S25460.
Yae T, Tsuchihashi K, Ishimoto T, Motohara T, Yoshikawa M, Yoshida GJ, Wada T, Masuko T, Mogushi K, Tanaka H, Osawa T. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nature communications. 2012 Jun 6;3(1):1-9.
Hozhabri H, Ghasemi Dehkohneh RS, Razavi SM, Razavi SM, Salarian F, Rasouli A, Azami J, Ghasemi Shiran M, Kardan Z, Farrokhzad N, Mikaeili Namini A. Comparative analysis of protein-protein interaction networks in metastatic breast cancer. PloS one. 2022 Jan 19;17(1):e0260584.
Abadi YM, Jeon H, Ohaegbulam KC, Scandiuzzi L, Ghosh K, Hofmeyer KA, Lee JS, Ray A, Gravekamp C, Zang X. Host b7x promotes pulmonary metastasis of breast cancer. The Journal of Immunology. 2013 Apr 1;190(7):3806-14.
Clézardin P. Therapeutic targets for bone metastases in breast cancer. Breast Cancer Research. 2011 Apr;13(2):1-9.
X
Dan Z, Cao H, He X, Zhang Z, Zou L, Zeng L, Xu Y, Yin Q, Xu M, Zhong D, Yu H. A pH-responsive host-guest nanosystem loading succinobucol suppresses lung metastasis of breast cancer. Theranostics. 2016;6(3):435.
Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, Downey RJ, Manova-Todorova K, Brogi E, Massagué J. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nature medicine. 2011 Jul;17(7):867-74.
Gao D, Joshi N, Choi H, Ryu S, Hahn M, Catena R, Sadik H, Argani P, Wagner P, Vahdat LT, Port JL. Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer research. 2012 Mar 15;72(6):1384-94.
Xu F, Wei Y, Tang Z, Liu B, Dong J. Tumor associated macrophages in lung cancer: Friend or foe?. Molecular Medicine Reports. 2020 Nov 1;22(5):4107-15.
Traverso N, Ricciarelli R, Nitti M, Marengo B, Furfaro AL, Pronzato MA, Marinari UM, Domenicotti C. Role of glutathione in cancer progression and chemoresistance. Oxidative medicine and cellular longevity. 2013 Oct;2013.
Gu P, Sun M, Li L, Yang Y, Jiang Z, Ge Y, Wang W, Mu W, Wang H. Breast Tumor-Derived Exosomal MicroRNA-200b-3p Promotes Specific Organ Metastasis Through Regulating CCL2 Expression in Lung Epithelial Cells. Frontiers in Cell and Developmental Biology. 2021 Jun 24;9:1572.
Welch DR. Metastasis Genes in Breast Cancer Metastasis to Bone. ALABAMA UNIV IN BIRMINGHAM; 2004 Jun 1.
Suva LJ, Griffin RJ, Makhoul I. Mechanisms of bone metastases of breast cancer. Endocrine-related cancer. 2009 Sep 1;16(3):703-13.
Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, Massagué J. A multigenic program mediating breast cancer metastasis to bone. Cancer cell. 2003 Jun 1;3(6):537-49.
Chen YC, Sosnoski DM, Mastro AM. Breast cancer metastasis to the bone: mechanisms of bone loss. Breast cancer research. 2010 Dec;12(6):1-1.
Käkönen SM, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2003 Feb 1;97(S3):834-9.
Khaitan D, Sankpal UT, Weksler B, Meister EA, Romero IA, Couraud PO, Ningaraj NS. Role of KCNMA1 gene in breast cancer invasion and metastasis to brain. BMC cancer. 2009 Dec;9(1):1-1.
Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system. The American journal of pathology. 2005 Oct 1;167(4):913-20.
Arshad F, Wang L, Sy C, Avraham S, Avraham HK. Blood-brain barrier integrity and breast cancer metastasis to the brain. Pathology research international. 2010 Dec 29;2011:920509-.
Lee JY, Park K, Lee E, Ahn T, Jung HH, Lim SH, Hong M, Do IG, Cho EY, Kim DH, Kim JY. Gene expression profiling of breast cancer brain metastasis. Scientific reports. 2016 Jun 24;6(1):1-0.
Hosonaga M, Saya H, Arima Y. Molecular and cellular mechanisms underlying brain metastasis of breast cancer. Cancer and Metastasis Reviews. 2020 Sep;39(3):711-20.
Paolillo M, Schinelli S. Brain infiltration by cancer cells: different roads to the same target?. Journal of Cancer Metastasis and Treatment. 2016 Mar 11;2:90-100.
Sirkisoon SR, Carpenter RL, Rimkus T, Miller L, Metheny-Barlow L, Lo HW. EGFR and HER2 signaling in breast cancer brain metastasis. Frontiers in bioscience (Elite edition). 2016;8:245.
Kodack DP, Chung E, Yamashita H, Incio J, Duyverman AM, Song Y, Farrar CT, Huang Y, Ager E, Kamoun W, Goel S. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proceedings of the National Academy of Sciences. 2012 Nov 6;109(45):E3119-27.
Bohn KA, Adkins CE, Nounou MI, Lockman PR. Inhibition of VEGF and angiopoietin-2 to reduce brain metastases of breast cancer burden. Frontiers in pharmacology. 2017 Apr 11;8:193.
Johnson KS, Conant EF, Soo MS. Molecular subtypes of breast cancer: a review for breast radiologists. Journal of Breast Imaging. 2021 Jan;3(1):12-24.
Fragomeni SM, Sciallis A, Jeruss JS. Molecular subtypes and local-regional control of breast cancer. Surgical Oncology Clinics. 2018 Jan 1;27(1):95-120.
García-Cortés D, Hernández-Lemus E, Espinal-Enríquez J. Luminal a breast cancer co-expression network: Structural and functional alterations. Frontiers in genetics. 2021;12.
Li ZH, Hu PH, Tu JH, Yu NS. Luminal B breast cancer: patterns of recurrence and clinical outcome. Oncotarget. 2016 Oct 4;7(40):65024.
Koo JS, Jung W, Jeong J. Metastatic breast cancer shows different immunohistochemical phenotype according to metastatic site. Tumori Journal. 2010 May;96(3):424-32.
Wulfkuhle JD, Speer R, Pierobon M, Laird J, Espina V, Deng J, Mammano E, Yang SX, Swain SM, Nitti D, Esserman LJ. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. Journal of proteome research. 2008 Apr 4;7(4):1508-17.
Tabaries S, Dong Z, Annis MG, Omeroglu A, Pepin F, Ouellet V, Russo C, Hassanain M, Metrakos P, Diaz Z, Basik M. Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. Oncogene. 2011 Mar;30(11):1318-28.
Martinez-Ordonez A, Seoane S, Cabezas P, Eiro N, Sendon-Lago J, Macia M, Garcia-Caballero T, Gonzalez LO, Sanchez L, Vizoso F, Perez-Fernandez R. Breast cancer metastasis to liver and lung is facilitated by Pit-1-CXCL12-CXCR4 axis. Oncogene. 2018 Mar;37(11):1430-44.
Khatib AM, Kontogiannea M, Fallavollita L, Jamison B, Meterissian S, Brodt P. Rapid induction of cytokine and E-selectin expression in the liver in response to metastatic tumor cells. Cancer research. 1999 Mar 15;59(6):1356-61.
Malanchi I, Santamaria-Martínez A, Susanto E, Peng H, Lehr HA, Delaloye JF, Huelsken J. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 2012 Jan;481(7379):85-9.
Sharma R, Sharma R, Khaket TP, Dutta C, Chakraborty B, Mukherjee TK. Breast cancer metastasis: Putative therapeutic role of vascular cell adhesion molecule-1. Cellular Oncology. 2017 Jun;40(3):199-208.
Chung S, Jin Y, Han B, Qu Y, Gao B, Giuliano AE, Cui X. Identification of EGF-NF-κB-FOXC1 signaling axis in basal-like breast cancer. Cell Communication and Signaling. 2017 Dec;15(1):1-9.
Yoneda T, Sasaki A, Mundy GR. Osteolytic bone metastasis in breast cancer. Breast cancer research and treatment. 1994 Jan;32(1):73-84.
Mastro AM, Gay CV, Welch DR, Donahue HJ, Jewell J, Mercer R, DiGirolamo D, Chislock EM, Guttridge K. Breast cancer cells induce osteoblast apoptosis: a possible contributor to bone degradation. Journal of cellular biochemistry. 2004 Feb 1;91(2):265-76.
Yae T, Tsuchihashi K, Ishimoto T, Motohara T, Yoshikawa M, Yoshida GJ, Wada T, Masuko T, Mogushi K, Tanaka H, Osawa T. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nature communications. 2012 Jun 6;3(1):1-9.
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
